Effect Of Methylprednisolone Sodium Succinate On The Prognosis Of Patients With Acute Ischemic Stroke After Thrombectomy

Objective: The purpose of this study was to investigate the therapeutic effect,safety,and prognostic impact of methylprednisolone sodium succinate(MPSS)on patients with acute ischemic stroke(AIS)undergoing thrombectomy.Methods:(1)This study collected 62 patients with AIS who were hospitalized in the Neurological Intensive Care Unit of the Affiliated Hospital of Youjiang Medical College for Nationalities from November 2021 to November 2022.(2)These patients(including 5 categories of internal carotid artery,anterior cerebral artery,middle cerebral artery,vertebral artery,and basilar artery occlusion)were randomly divided into two groups.The patients with AIS were divided into control group and study group according to whether they received methylprednisolone sodium succinate treatment after the embolectomy performed by the same chief physician of neurology within the treatment time window.The study group received intravenous medication of 2 mg/Kg MPSS for 3 days.The patients in both groups received medication,rehabilitation training,and other measures according to the treatment guidelines after surgery.(3)The differences in NIHSS scores,modified Rankin(m RS)scale scores,complication rates,and mortality rates between the two groups of AIS patients 7 days and 3 months after surgery were statistically compared.Results:(1)There was no significant difference between the study group and the control group in age,gender composition,onset time,drinking history,smoking history,hypertension,diabetes,coronary heart disease,hyperhomocysteinemia,blood lipid(total cholesterol,triglyceride)levels,m RS score at admission,NIHSS score,GCS score and other aspects(P>0.05).(2)There was also no significant difference in the proportion of responsible vessels between the study group and the control group(P>0.05).(3)The NIHSS score and m RS score in the study group and the control group gradually decreased after admission,7 days and 3months of admission,and the neurological deficit score in the study group was significantly higher than that in the control group on 7 days of admission(P<0.05).(4)In the control group,10 people(32.3%)had a higher NIHSS score on the 7th day of admission than at admission,while in the study group,9 people(29.0%)had a higher NIHSS score on the 7th day of admission.(5)There were also no significant differences in the incidence and mortality of complications such as cerebral hernia,pulmonary infection,and gastrointestinal bleeding between the study group and the control group(P>0.05).Conclusion:(1)Intravenous use of MPSS in AIS patients after thrombectomy may lead to an aggravation of neurological deficits in the short term,but it does not affect long-term neurological recovery,nor does it increase the risk of complications and death.(2)Due to the small number of cases enrolled in this study,which may lead to deviation in the results,prospective studies of intravenous methylprednisolone sodium succinate after surgery will continue.